Novel agents for B-cell non-Hodgkin lymphoma: science and the promise [0.03%]
治疗B细胞非霍奇金淋巴瘤的新药：从科学到临床展望
Kevin Tay,Kieron Dunleavy,Wyndham H Wilson
Kevin Tay
There has been tremendous insight gained in the last two decades from basic science research. New molecular targets in neoplastic cells are emerging and provide the rationale for clinical development of novel agents in non-Hodgkin lymphoma....
Adlette Inati
Adlette Inati
Appropriate blood transfusions can both prevent and treat serious complications related to sickle cell disease (SCD), but inevitably lead to iron overload and its complications in terms of morbidity and mortality. Transfusion history and se...
John B Porter
John B Porter
beta-thalassaemia has served as a paradigm for chelation management for over three decades, both in terms of defining the complications of transfusional iron overload, and demonstrating the benefits of chelation therapy. Iron chelation ther...
Iron chelation therapy in MDS: what have we learnt recently? [0.03%]
低氧诱导因子-脯氨酰羟化酶抑制剂在骨髓增生异常综合征中的应用进展
Mathias Schmid
Mathias Schmid
Patients with myelodysplastic syndromes (MDS) who receive chronic blood transfusions for anaemia are at risk of developing iron overload, which can negatively affect organ function and survival. Evidence suggests that iron chelation therapy...
Pierre Fenaux,Christian Rose
Pierre Fenaux
Anaemia is prevalent in patients with myelodysplastic syndromes (MDS), and most patients with MDS receive regular red blood cell transfusions, which can lead to iron overload. Some patients may already have iron overload before transfusions...
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction [0.03%]
铁毒性：输血依赖性贫血的螯合治疗优化。概述
John B Porter
John B Porter
Paul Monagle,Vera Ignjatovic,Helen Savoia
Paul Monagle
Developmental Hemostasis refers to the age-related changes in the coagulation system that are most marked during neonatal life and childhood. An understanding of these changes is crucial to the accurate diagnosis of hemostatic abnormalities...
Current therapeutic approaches to fungal infections in immunocompromised hematological patients [0.03%]
血液系统恶性肿瘤患者合并真菌感染的治疗进展
Livio Pagano,Morena Caira,Caterina Giovanna Valentini et al.
Livio Pagano et al.
Invasive fungal infections are significant causes of morbidity and mortality in patients with hematological malignancies. Patients with acute myeloid leukemia and those who have undergone allogeneic hematopoietic stem cell transplantation a...
Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data [0.03%]
耐药酪氨酸激酶抑制剂的慢性髓性白血病优化疗法——临床和实验室数据汇总分析
David A Irvine,Nicholas B Heaney,Tessa L Holyoake
David A Irvine
The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that targets the BCR-ABL protein, has revolutionised the treatment of chronic myeloid leukaemia (CML), producing high rates of response that have been durable in many patients....
Inhibitory anti-ADAMTS 13 antibodies: measurement and clinical application [0.03%]
抗ADAMTS13自身抗体的检测及其临床意义
Marie Scully
Marie Scully
Thrombotic thrombocytopenic purpura is an acute life threatening disorder, characterised by thrombocytopenia, microangiopathic haemolytic anaemia and multi organ microvascular thrombi that results in variable clinical symptoms. Just over a ...